Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
A. Enrique Caballero MD

A. Enrique Caballero MD

Associate Professor of Medicine, Harvard Medical School; Director, Latino Diabetes Health, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital; Director, Diabetes Education, Postgraduate Medical Education at Harvard Medical School, Boston, Massachusetts

Dr. A. Enrique Caballero is an Endocrinologist, Investigator and Educator. He is the Director of International Innovation Programs in the Office for External Education and the Director of Diabetes Education in the Postgraduate Medical Education Department at Harvard Medical School (HMS) where he leads the development of education programs that benefit health care professionals and patients around the world. He is Associate Professor of Medicine at HMS.

He is also the Director of Latino Diabetes Health in the Division of Endocrinology, Diabetes and Hypertension an Associate Scientist in the Division of Global Health Equity at the Brigham and Hospital (BWH) in Boston, MA. He is the recipient of the 2022 Harvard Medical School Harold Amos prestigious award that recognizes exemplary work on Diversity, Inclusion and Equity in Health Care. He is also the recipient of the 2023 American Diabetes Association’s Outstanding Educator in Diabetes Award and the 2024 Endocrine’s Society Outstanding Educator Award.

Disclosures

Dr. Caballero has no relevant disclosures.

Recent Contributions to PracticeUpdate:

  1. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes